Pharma Bulls, Intel Bears: Today's Analyst Moves

Wells Fargo dominated analyst activity on Friday, with a sweeping set of target price changes across pharma and healthcare.

The biggest upward call went to LLY. Wells Fargo raised its target on Eli Lilly from $1,330 to $1,500, keeping a Buy rating. The $1.2 trillion drug giant carries short interest of just 0.8% of free float. That reflects near-universal confidence in the GLP-1 growth story.

Also at Wells Fargo, analyst Mohit Bansal lifted his target on GILD from $165 to $190, a 15% jump. Gilead shares carry a $205 billion market cap and short interest of just 1.6% of free float.

The sharpest cut of the session came from Truist Securities. Analyst William Stein slashed his target on INTC from $108 to $72, a 33% reduction, while keeping a Hold rating. That is a striking move for a stock with a $484 billion market cap. Short interest sits at 3.2% of free float, low by sector standards, but the target cut signals continued pressure on Intel's competitive position in semiconductors.

Truist also lifted its target on infrastructure play PWR to $967, maintaining a Buy. Quanta Services has 25 Buy ratings from analysts versus just one Sell. That consensus is one of the strongest in the current dataset.

RDDT saw its target trimmed from $275 to $210 by Truist's Youssef Squali. The Buy rating was held, but the cut suggests near-term caution despite Reddit's strong ad market positioning.